Convalescent plasma (CP) from recovered patients with COVID-19 doesn’t prevent further COVID-19 progression in at-risk people who visit the emergency room (ER).

Early this week, the National Institutes of Health (NIH) stopped a trial it was running on convalescent plasma after an independent review committee found the therapy was providing no clear meaningful benefit for patients with COVID-19 who were treated and released from the ER.

The new trial, termed the Clinical Trial of COVID-19 Convalescent Plasma of Outpatients (C3PO), only included 511 participants out of its 900-participant goal.

Overall, the trial was conducted at 47 hospital emergency departments.

Patients were included if they had COVID-19 symptoms for a week or less.

At this moment, there is no high quality evidence to support the efficacy of convalescent plasma for treating COVID-19 illness.

Read More